Download PDF
PiD - Psychotherapie im Dialog 2013; 14(02): 86-90
DOI: 10.1055/s-0033-1348373
Über den Tellerrand
© Georg Thieme Verlag KG Stuttgart · New York

Pharmakotherapie bei erektiler Dysfunktion

Alles, was Sie über Viagra & Co wissen sollten
Armin Soave
,
Michael Rink
,
Margit Fisch
,
Roland Dahlem
Further Information

Publication History

Publication Date:
03 July 2013 (online)

Also available at
    Permissions and Reprints

Die erektile Dysfunktion (ED) ist die häufigste sexuelle Funktionsstörung des Mannes. Sie ist definiert als persistierendes Unvermögen, Erektionen erreichen oder aufrechterhalten zu können. Die verschiedenen Schweregrade reichen von mild bis schwer, sie werden durch den International Index of Erectile Function Index (IIEF) klassifiziert ([Hatzimouratidis et al. 2010] ). Mit Einführung der Phosphodiesterase-5-Hemmer (PDE5-Hemmer) wurde die medikamentöse ED-Therapie effektiver, einfacher und nebenwirkungsärmer. Dieser Übersichtsartikel gibt eine kurze Einführung in die Grundlagen der ED und erläutert Indikationen und Optionen bei der medikamentösen Therapie.

 

  • Literatur

  • Afif-Abdo J, Teloken C, Damiao R et al. Comparative Cross-Over Study of Sildenafil and Apomorphine for Treating Erectile Dysfunction. BJU Int 2008; 102: 829-834
    CrossrefPubMedSearch in Google Scholar
  • Althof SE.. Quality of Life and Erectile Dysfunction. Urology 2002; 59: 803-810
    CrossrefPubMedSearch in Google Scholar
  • Bechara A, Casabé A, De Bonis W et al. Recreational Use of Phosphodiesterase Type 5 Inhibitors by Healthy Young Men. J Sex Med 2010; 7: 3736-3742
    CrossrefPubMedSearch in Google Scholar
  • Braun M, Wassmer G, Klotz T et al. Epidemiology of Erectile Dysfunction: Results of the ‚Cologne Male Survey‘. Int J Impot Res 2000; 12: 305-311
    Search in Google Scholar
  • Briganti A, Chun FK, Salonia A et al. A Comparative Review of Apomorphine Formulations for Erectile Dysfunction: Recommendations for Use in the Elderly. Drugs Aging 2006; 23: 309-319
    CrossrefPubMedSearch in Google Scholar
  • Chughtai B, Lee RK, Te AE, Kaplan SA. Metabolic Syndrome and sexual Dysfunction. Curr Opin Urol 2011; 21: 514-518
    CrossrefPubMedSearch in Google Scholar
  • Corona G, Mondaini N, Ungar A et al. Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction: The Proper Drug for the Proper Patient. J Sex Med 2011; 8: 3418-3432
    CrossrefPubMedSearch in Google Scholar
  • Dhir RR, Lin HC, Canfield SE, Wang R. Combination Therapy for Erectile Dysfunction: An Update Review. Asian J Androl 2011; 13: 382-390
    CrossrefPubMedSearch in Google Scholar
  • Ding H, Du W, Wang H et al. Efficacy and Safety of Udenafil for Erectile Dysfunction: A Meta-Analysis of Randomized Controlled Trials. Urology 2012; 80: 134-139
    CrossrefPubMedSearch in Google Scholar
  • Donatucci CF, Wong DG, Giuliano F et al. Efficacy and Safety of Tadalafil Once Daily: Considerations for the Practical Application of a Daily Dosing Option. Curr Med Res Opin 2008; 24: 3383-3392
    CrossrefPubMedSearch in Google Scholar
  • Esposito K, Ciotola M, Giugliano F et al. Effects of Intensive LifeStyle Changes on Erectile Dysfunction in Men. J Sex Med 2009; 6: 243-250
    CrossrefPubMedSearch in Google Scholar
  • Hatzimouratidis K, Amar E, Eardley I et al. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. Europ Urol 2010; 57: 804-814
    CrossrefPubMedSearch in Google Scholar
  • Jackson G, Boon N, Eardley I et al. Erectile Dysfunction and Coronary Artery Disease Prediction: Evidence-Based Guidance and Consensus. Int J Clin Pract 2010; 64: 848-857
    CrossrefPubMedSearch in Google Scholar
  • Korkes F, Costa-Matos A, Gasperini R et al. Recreational Use of PDE5 Inhibitors by Young Healthy Men: Recognizing this Issue among Medical Students. J Sex Med 2008; 5: 2414-2418
    PubMedSearch in Google Scholar
  • Kumar R, Nehra A. Central Nervous System Agents and Erectile Dysfunction. Urol Clin North Am 2011; 38: 165-173
    CrossrefPubMedSearch in Google Scholar
  • Laumann EO, Paik A, Rosen RC. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA 1999; 281: 537-544
    CrossrefPubMedSearch in Google Scholar
  • McMahon C. Comparison of Efficacy, Safety, and Tolerability of On-Demand Tadalafil and Daily Dosed Tadalafil for the Treatment of Erectile Dysfunction. J Sex Med 2005; 2: 415-425 discussion 425–417
    CrossrefPubMedSearch in Google Scholar
  • Melnik T, Soares BG, Nasselo AG. Psychosocial Interventions for Erectile Dysfunction. Cochrane Database Syst Rev 2007; 18 CD004825
    PubMedSearch in Google Scholar
  • Melnik T, Soares BG, Nasello AG. The Effectiveness of Psychological Interventions for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis, Including Comparisons to Sildenafil Treatment, Intracavernosal Injection, and vacuum Devices. J Sex Med 2008; 5: 2562-2574
    CrossrefPubMedSearch in Google Scholar
  • Phe V, Roupret M. Erectile Dysfunction and Diabetes: A Review of the Current Evidence-Based Medicine and a Synthesis of the Main Available Therapies. Diabetes Metab 2012; 38: 1-13
    PubMedSearch in Google Scholar
  • Park HJ, Choi HK, Ahn TY et al. Efficacy and Safety of Oral Mirodenafil in the Treatment of Erectile Dysfunction in Diabetic Men in Korea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled clinical Trial. J Sex Med 2010; 7: 2842-2850
    CrossrefPubMedSearch in Google Scholar
  • Porst H, Hell-Momeni K, Büttner H. Chronische PDE-5-Hemmung bei erektiler Dysfunktion. Urologe 2009; 48: 1318-1329
    CrossrefPubMedSearch in Google Scholar
  • Segal R, Burnett AL. Avanafil for the Treatment of Erectile DysFunction. Drugs Today (Barc) 2012; 48: 7-15
    PubMedSearch in Google Scholar
  • Tsertsvadze A, Fink HA, Yazdi F et al. Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-Analysis. Ann Intern Medicine 2009; 151: 650-661
    PubMedSearch in Google Scholar
  • Ude M, Ude C, Leuner K. Nitrate und PDE5-Hemmer: Pharmazeutische Betreuung. Therapiebegleitende Beratung in der Apotheke. Pharmazie in unserer Zeit 2010; 39: 397-404
    PubMedSearch in Google Scholar
  • Washington SL, Shindel AW. A Once-Daily Dose of Tadalafil for Erectile Dysfunction: Compliance and Efficacy. Drug Des Devel Ther 2010; 4: 159-171
    PubMedSearch in Google Scholar
  • Zhang X, Feng Q, Cote RH. Efficacy and Selectivity of Phosphodiesterase-Targeted Drugs in Inhibiting Photoreceptor Phosphodiesterase (PDE6) in Retinal Photoreceptors. Invest Ophthalmol Vis Sci 2005; 46: 3060-3066
    CrossrefPubMedSearch in Google Scholar